Teck Boon Low

1.2k total citations
19 papers, 436 citations indexed

About

Teck Boon Low is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Infectious Diseases. According to data from OpenAlex, Teck Boon Low has authored 19 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 5 papers in Epidemiology and 3 papers in Infectious Diseases. Recurrent topics in Teck Boon Low's work include Cystic Fibrosis Research Advances (8 papers), Neonatal Respiratory Health Research (5 papers) and Tracheal and airway disorders (4 papers). Teck Boon Low is often cited by papers focused on Cystic Fibrosis Research Advances (8 papers), Neonatal Respiratory Health Research (5 papers) and Tracheal and airway disorders (4 papers). Teck Boon Low collaborates with scholars based in Singapore, Ireland and United Kingdom. Teck Boon Low's co-authors include Noel G. McElvaney, Catherine M. Greene, Shane O’Neill, Emer Kelly, Sinéad Weldon, Clifford C. Taggart, Sally‐Ann Cryan, Sanjay H. Chotirmall, Tidi Hassan and Emer P. Reeves and has published in prestigious journals such as The Journal of Experimental Medicine, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Teck Boon Low

19 papers receiving 429 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Teck Boon Low Singapore 9 222 98 78 76 71 19 436
Mark P. Rogan Ireland 8 330 1.5× 79 0.8× 126 1.6× 45 0.6× 38 0.5× 11 589
Anna G. Drannik Canada 11 130 0.6× 158 1.6× 95 1.2× 79 1.0× 43 0.6× 12 485
Yuzaburo Inoue Japan 15 135 0.6× 183 1.9× 108 1.4× 186 2.4× 32 0.5× 53 607
Jatinder K. Juss United Kingdom 11 117 0.5× 253 2.6× 123 1.6× 45 0.6× 57 0.8× 16 526
Laleh Sharifi Iran 14 107 0.5× 305 3.1× 112 1.4× 57 0.8× 45 0.6× 57 598
Catherine Ptaschinski United States 15 188 0.8× 274 2.8× 143 1.8× 92 1.2× 81 1.1× 28 643
Matthew Dickinson United States 5 383 1.7× 381 3.9× 145 1.9× 115 1.5× 65 0.9× 6 781
Hiroshi Fujiwara Japan 15 106 0.5× 127 1.3× 114 1.5× 109 1.4× 32 0.5× 62 587
Martha Pérez‐Rodríguez Mexico 18 94 0.4× 364 3.7× 111 1.4× 30 0.4× 66 0.9× 35 672
Hsiao Hui Ong Singapore 11 99 0.4× 183 1.9× 212 2.7× 101 1.3× 46 0.6× 27 581

Countries citing papers authored by Teck Boon Low

Since Specialization
Citations

This map shows the geographic impact of Teck Boon Low's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teck Boon Low with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teck Boon Low more than expected).

Fields of papers citing papers by Teck Boon Low

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teck Boon Low. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teck Boon Low. The network helps show where Teck Boon Low may publish in the future.

Co-authorship network of co-authors of Teck Boon Low

This figure shows the co-authorship network connecting the top 25 collaborators of Teck Boon Low. A scholar is included among the top collaborators of Teck Boon Low based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teck Boon Low. Teck Boon Low is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Low, Teck Boon, et al.. (2022). Characterisation of the post-tuberculous phenotype of bronchiectasis: A real-world observational study. Chronic Respiratory Disease. 19. 4063523034–4063523034. 13 indexed citations
2.
Tiew, Pei Yee, Albert Yick Hou Lim, Holly R. Keir, et al.. (2021). High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap. CHEST Journal. 161(1). 40–53. 16 indexed citations
3.
Saini, Monica, et al.. (2021). Transient global amnesia and focal diffusion weighted imaging lesions in mesiotemporal region: A ten-year experience. Clinical Neurology and Neurosurgery. 202. 106522–106522. 2 indexed citations
4.
Narayana, Jayanth Kumar, Micheál Mac Aogáin, Pei Yee Tiew, et al.. (2020). “Integrative microbiomics” reveals a disrupted interactome in bronchiectasis exacerbations. 4102–4102. 1 indexed citations
5.
Aogáin, Micheál Mac, Zhao Cai, Rikky W. Purbojati, et al.. (2019). The airway ‘resistome’ in chronic respiratory disease: a metagenomics approach. OA5141–OA5141. 2 indexed citations
6.
Thng, Kai Xian, Micheál Mac Aogáin, Nur A’tikah Binte Mohamed Ali, et al.. (2019). Viral prevalence in stable bronchiectasis: analysis of the Cohort of Asian and Matched European Bronchiectasis (CAMEB). PA2875–PA2875. 2 indexed citations
7.
Tran, The-Thien, Céline Vidaillac, Hong Yu, et al.. (2018). A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart. International Journal of Pharmaceutics. 547(1-2). 368–376. 16 indexed citations
8.
Quah, Jessica, Teck Boon Low, & Raymond Fong. (2018). Disseminated Cryptococcus gattii infection preceding onset of pulmonary alveolar proteinosis. Respirology Case Reports. 6(7). e00357–e00357. 8 indexed citations
9.
Tran, The-Thien, Céline Vidaillac, R Chandrasekaran, et al.. (2017). Inhalable Ciprofloxacin-Nanoplex (CIP-Np) combined with mannitol as a novel bronchiectasis therapeutic. PA4120–PA4120. 1 indexed citations
10.
Quah, Jessica, et al.. (2016). Cryptococcus gatti Infection With Pulmonary and CNS Involvement in an Immunocompetent Patient. CHEST Journal. 149(4). A117–A117. 1 indexed citations
11.
How, Choon How, et al.. (2016). A simplified approach to haemoptysis. Singapore Medical Journal. 57(8). 415–418. 5 indexed citations
12.
Lee, Lynette, et al.. (2016). A Rare Tracheal Tumour: Inverted Schneiderian Papilloma. CHEST Journal. 149(4). A430–A430. 1 indexed citations
13.
Chotirmall, Sanjay H., J. A. A. Renwick, Tidi Hassan, et al.. (2012). The Effect of Aspergillus fumigatus Infection on Vitamin D Receptor Expression in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 186(10). 999–1007. 83 indexed citations
14.
Chotirmall, Sanjay H., J. A. A. Renwick, Tidi Hassan, et al.. (2012). Itraconazole Up-Regulates The Vitamin D Receptor And Reduces T-Helper 2 Responses In Aspergillus Fumigatus Colonised Individuals With Cystic Fibrosis. A2807–A2807. 1 indexed citations
15.
Reeves, Emer P., David A. Bergin, Elaine Hayes, et al.. (2011). A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis. 11(2). 100–107. 11 indexed citations
16.
Bergin, David A., Emer P. Reeves, Elaine Hayes, et al.. (2011). Neutrophil Derived CD16B: Alpha-1 Antitrypsin Complex; A Novel Biomarker Of Inflammation In Cystic Fibrosis. A5739–A5739. 1 indexed citations
17.
Low, Teck Boon, Catherine M. Greene, Shane O’Neill, & Noel G. McElvaney. (2011). Quantification and Evaluation of the Role of Antielastin Autoantibodies in the Emphysematous Lung. Pulmonary Medicine. 2011. 1–6. 19 indexed citations
18.
Greene, Catherine M., Teck Boon Low, Shane O’Neill, & Noel G. McElvaney. (2009). Anti–Proline-Glycine-Proline or Antielastin Autoantibodies Are Not Evident in Chronic Inflammatory Lung Disease. American Journal of Respiratory and Critical Care Medicine. 181(1). 31–35. 57 indexed citations
19.
Taggart, Clifford C., Sally‐Ann Cryan, Sinéad Weldon, et al.. (2005). Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding. The Journal of Experimental Medicine. 202(12). 1659–1668. 196 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark P. Rogan Breakdown of academic impact, for papers by Anna G. Drannik Breakdown of academic impact, for papers by Yuzaburo Inoue Breakdown of academic impact, for papers by Jatinder K. Juss Breakdown of academic impact, for papers by Laleh Sharifi Breakdown of academic impact, for papers by Catherine Ptaschinski Breakdown of academic impact, for papers by Matthew Dickinson Breakdown of academic impact, for papers by Hiroshi Fujiwara Breakdown of academic impact, for papers by Martha Pérez‐Rodríguez Breakdown of academic impact, for papers by Hsiao Hui Ong
Rankless by CCL
2026